Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Morpholine | HCID 8083 | — |
| Reactant | HCID 59244923 | HCID 59244923 | — |
| Product | HCID 67386066 | HCID 67386066 | 87.7% |
Reaction Steps
Using 3-(4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-benzoic acid (38.2 mg, 0.0579 mmol) obtained in Step A instead of 4-(4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-benzoic acid, and morpholine (10.1 μl, 0.116 mmol) instead of 3-(aminomethyl)pyridine, in the same manner as Step B in Example 1-D-19, amidation was carried out, to obtain a crude product of {3-[4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl]-phenyl}-morpholin-4-yl-methanone as a yellow liquid (37 mg), and then the PMB groups were removed according to the above Deprotection method 2, to obtain the desired compound (D-53) as a yellow powder (22.3 mg, 78%).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08022205B2 |
|---|
| Source dataset | uspto-grants-2011_09 |
|---|
| ORD ID | ord-af95736018e649ca918156a7a4d7b6be |
|---|
| Source note | uspto-grants-2011_09 |
|---|